Quarterly Consolidated Financial Results for the 1st Quarter, Ended June 30, 2024
(Japanese GAAP)
August 8, 2024
Name of Listed Company: Kaneka Corporation
Stock Exchange Listing: Tokyo
Code Number:
4118
URL https://www.kaneka.co.jp/en/
Representative: Kazuhiko Fujii, President, Representative Director
Contact Person: Osamu Ishida, Managing Executive Officer – Investors & Public Relations Department
Phone: +81-3-5574-8090
Scheduled date of dividend distribution: －Note: Figures have been rounded down to the nearest million yen.

1. Consolidated Financial Results for the 1st Quarter, Ended June 30, 2024
(from April 1, 2024 to June 30, 2024)(1) Consolidated operating results(% indicates year-on-year change)
Net sales¥ million% ¥ million

198,382
182,740

Apr.1, 2024 – Jun. 30, 2024
Apr.1, 2023 – Jun. 30, 2023

income attributable
Ordinary income Net
to owners of parent

Operating income

8.6
(5.2)

% ¥ million

10,276
5,603

83.4(54.1)% ¥ million

10,146
6,674

52.0(54.8)

7,033
4,241

%

65.8
(59.7)

Note: Comprehensive income: ¥15,678 million [(8.4%)] for the three months ended June 30, 2024
¥17,123 million [(3.1%)] for the three months ended June 30, 2023

Basic net income
Diluted net
per share
income per share¥¥

110.3865.35

Apr.1, 2024 – Jun. 30, 2024
Apr.1, 2023 – Jun. 30, 2023

110.0465.17(2) Consolidated financial position
Total assets¥ million

As of June 30, 2024
As of March 31, 2024

Net assets

886,224
870,205¥ million

Equity ratio%

481,391
474,383

51.9
52.1

Reference: Equity (Shareholders’ equity + Accumulated other comprehensive income):¥459,895 million as of June 30, 2024
¥453,463 million as of March 31, 2024

2. Dividends
Annual dividends
1st Quarter 2nd Quarter 3rd Quarter¥¥

Apr.1, 2023 – Mar. 31, 2024－

Apr.1, 2024 – Mar. 31, 2025－

Apr.1, 2024 – Mar. 31, 2025
(Forecasts)¥

Year-end¥

Annual
¥

55.00

－

55.00

110.00

60.00

－

60.00

120.00Note: Changes in dividend forecast during the quarter under review: None
3. Forecast for Consolidated Financial Results for the Fiscal Year Ending March 31, 2025
(from April 1, 2024 to March 31, 2025)(Percentage figures represent changes from the corresponding periods of the previous fiscal year)
Net income
Operating
Net income
attributableto
Net sales
Ordinary income
incomeper shareowners of parent¥ million

Full year

790,000% ¥ million

3.6

38,000% ¥ million

16.6

34,000% ¥ million

16.3 24,500

%¥

5.5

388.18

Note: Revisions to consolidated business performance forecasts during the quarter under review: None

※ Notes(1) Changes in the scope of consolidation during the term: None
(2) Application of simplified methods of accounting and specific accounting methods: None
(3) Changes in accounting principles, changes in estimates, or restatements
1. Changes owing to revisions in accounting standards: Yes
2. Changes other than 1. above: None
3. Changes in accounting estimates: None
4. Restatements: None
Note: For details, please refer to the section entitled “(3) Notes to the Consolidated Financial
Statements (Changes in Accounting Policy)” under “2. Quarterly Consolidated Financial
Statements and Main Notes” on page 10.
(4) Number of shares issued (common stock)
1. Number of shares issued at the end of the period(including treasury stock):
2. Number of shares of treasury stock at the end of theperiod:3. Average number of shares outstanding during the period(calculated cumulatively from the beginning of the fiscal year):

June 30, 2024

66,000,000

March 31, 2024

sharesJune 30, 2024

3,089,830

sharesMarch 31, 2024

1,851,007June 30, 2023

64,900,739

sharesJune 30, 2024

63,726,032
shares

66,000,000

sharesshares※ Review of the accompanying quarterly consolidated financial statements by certified public
accountants or an audit firm：None※Explanations or other items pertaining to appropriate use of business performance forecasts
The business performance forecasts and certain other statements contained in this document
forward-looking statements, which are based on information currently available to the Company
and certain assumptions determined to be reasonable by the Company. For a variety of reasons,actual performance may differ substantially from these forecasts. They do not constitute a
guarantee that the Company will achieve these forecasts or other forward-looking statements. For
cautionary items used in business performance forecasts, please refer to the section entitled “(3)Earnings Forecasts and Other Forward-looking Statements” under “1. Quarterly Consolidated
Financial Results” on page 5.

Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

Supplementary Materials
Contents
1. Quarterly Consolidated Financial Results -------------------------------------------------------------- P. 2
(1) Operating Results -------------------------------------------------------------------------------------- P. 2
(2) Financial Position --------------------------------------------------------------------------------------- P. 4
(3) Earnings Forecasts and Other Forward-looking Statements -------------------------------- P. 5
2. Quarterly Consolidated Financial Statements and Main Notes --------------------------------- P. 6
(1) Quarterly Consolidated Balance Sheets ---------------------------------------------------------- P. 6(2) Quarterly Consolidated Statements of Income and Comprehensive Income ------------ P. 8
(3) Notes to the Consolidated Financial Statements ----------------------------------------------- P. 10(Changes in Accounting Policy) --------------------------------------------------------------------- P. 10(Segment Information) -------------------------------------------------------------------------------- P. 10(Notes in the Event of Significant Changes in the Amount of Shareholders’ Equity) --- P. 11(Going Concern Assumption) ------------------------------------------------------------------------ P. 11(Notes on Quarterly Consolidated Statements of Cash Flows) ----------------------------- P. 11- 1 -Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

1. Quarterly Consolidated Financial Results(1) Operating Results➢

State of Global Economy - Ongoing standstill without a clear direction, in spite of signs of recovery During the first three months (April 1 to June 30, 2024, “1Q”) of the fiscal year ending March 31, 2025, theglobal economy showed a moderate recovery trend due to easing inflationary pressure around the world.
However, the pace of recovery remained slow. With no signs of subsidence of geopolitical risks, such as
prolonged conflicts and unstable global political situation, the global economy remains lacking in a clear
direction. While the economy is at an ongoing standstill in Europe and the U.S., the outlook of China’s
economic recovery is still uncertain. Meanwhile, the Japanese manufacturing industry was adversely
affected by automobile production cutbacks and slowing overseas demand amid the record depreciationof the yen.

➢

Kaneka Group’s Business Performance - Sales and profits increased, getting off a solid start with
continued recovery momentum Under these circumstances, Kaneka Group’s business performance for 1Q was as follows. Consolidated
net sales were ¥198,382 million (up 8.6% year-on-year), operating income was ¥10,276 million (up 83.4%
year-on-year), ordinary income was ¥10,146 million (up 52.0% year-on-year), and net income attributableto owners of parent was ¥7,033 million (up 65.8% year-on-year).
Under the unstable demand environment, the Group recorded significant year-on-year increases across
key indicators, including net sales, operating income, ordinary income, and net income attributable toowners of parent. In particular, operating income has shown a steady recovery every quarter since thesame period of last fiscal year.

Business performance for the first three months (April 1, 2024 to June 30, 2024) (Millions of yen)
FY20241Q(Apr.-Jun.)

FY20231Q(Apr.-Jun.)
182,740

198,382

Operating income

5,603

10,276

Ordinary income

6,674

10,146

Net income attributable toowners of parent

4,241

7,033

Net sales

Difference(year-on-year)
15,642
8.6%
4,673
83.4%
3,472
52.0%
2,792
65.8%

Net sales by business segment(Millions of yen)
Net sales

FY2023

FY2024

1Q

2Q

3Q

4Q

1Q

Material SU

77,65978,81481,44484,982

86,042

Quality of Life SU

40,87843,88046,63844,78545,058

Health Care SU

17,74518,44817,20921,452

18,372

Nutrition SU

46,03746,00649,03846,09948,674

419

226

280

252

234

182,740

187,376

194,611

197,574

198,382

OthersTotal※SU：Solutions Unit

-2-

Difference(year-on-year)

8,382
10.8%
4,180
10.2%
626
3.5%
2,637
5.7%
(184)
(44.1%)
15,642
8.6%

Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

Operating income by business segment(Millions of yen)
Operating income

FY2023

FY2024

1Q

2Q

3Q

4Q

1Q

Material SU

5,513

6,610

6,996

8,375

8,382

Quality of Life SU

2,939

4,159

4,655

3,607

4,256

Health Care SU

2,967

2,926

2,451

4,596

2,992

Nutrition SU

2,277

2,298

3,820

3,680

3,903

288

101

151

125

111

Adjustment(8,381)(9,093)(9,070)(9,417)(9,369)

Total

5,603

7,002

9,004

10,968

10,276

OthersDifference(year-on-year)

2,869
52.0%
1,316
44.8%
25
0.9%
1,626
71.4%
(176)
(61.3%)
(988)
4,673
83.4%

※SU：Solutions Unit

The operating performance by business segment was as follows:① Material Solutions Unit➢

This unit recorded increased sales and profits in all Solutions Vehicles due to a moderate recovery indemand in Europe, the U.S., and Asia.
For Vinyls and Chlor-Alkali, both PVC and caustic soda resulted in an increase in profits due to the current
demand on a recovery track amid sluggish market conditions in Asia. As part of ongoing efforts to improve
profit margin, the Group has announced a price revision for PVC in Japan.

➢

For Modifiers, in addition to contribution from our cost reduction efforts, demand recovered at all locations,
resulting in a significant increase in profits. With steady sales expansion of products for non-PVC use andepoxy masterbatch (MX), we will accelerate a shift to high-value-added products.

➢

For Modified Silicone polymers, profits increased due to solid sales expansion driven by taking advantageof their unique functional characteristics. We will focus on expanding sales in new applications and new
regions from the second quarter (July 1 to September 30, 2024) of the current fiscal year onward,
leveraging increased production capacity of our facilities in Belgium.

➢

For Green Planet, progress has been made in collaboration with major brand holders around the world,
resulting in a further increase in product adoption, such as being adopted as a foam cushioning material
for home electrical appliances and automobiles. Recognizing a growing interest in Green Planet with thetightening of environmental regulations across the globe, we will steadily proceed with the launch of ademonstration plant for the mass production of Green Planet.

② Quality of Life Solutions Unit➢

This unit resulted in significant increases in both sales and profits all together. While the Foam & Residential
Techs business was adversely affected by production adjustments in the automobile sector, the E & I
Technology business saw a recovery in demand for smartphones.
Foam & Residential Techs was affected negatively by production adjustments in the automobile sectors aswell as by slumping demand in the agricultural and fishery and construction sectors. We will continue
working to improve profit margin by, among other means, securing demand, revising prices, and reducing
costs.

➢For E & I Technology, shipments of both polyimide films and acrylic resins increased significantly due toincreased production of smartphones and large-screen TVs. With the increased use of 5G smartphones,
the number of items adopting Pixeo™ for high frequency applications has also increased.

➢

For PV & Energy management, the sales of high-efficiency photovoltaic modules for residential use
remained firm. The launch of microgrid businesses in Toyooka City; growing demand for zero-energy-3-Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

building (ZEB), in which walls and windows generate electricity; and progress made in public and private
collaborative efforts to introduce a next-generation photovoltaic module (perovskite) have been drawing
further attention to our products.
➢

For Performance Fibers, it has been taking longer than expected for demand for hair accessory products
to recover because of the persistent currency depreciation and high inflation in African countries. We will
work to further stimulate demand by expanding sales to all over Sub-Saharan Africa and accelerating the
introduction of new high-performance products.

③ Health Care Solutions Unit➢

This unit as a whole resulted in increases in both sales and profits mainly due to the Medical business
continued showing solid business performance while the Pharma business was adversely affected bydemand fluctuations compared to the previous quarter. We expect the unit to continue enjoying steady
growth.
For Medical, the sales of both blood purification devices and catheters have been expanding steadily. A
new production facility for blood purification devices in Hokkaido is scheduled to start its operations inAugust this year, and it is expected to contribute to increasing demand in and outside Japan from thesecond half of the fiscal year onward. For catheters, we will launch new products in the areas ofgastroenterology and arrhythmia. We are also considering constructing a new catheter production facility.

➢

For Pharma, steady progress has been made in projects for newly developed products in both small
molecule pharmaceuticals and biopharmaceuticals, despite being affected by a demand change in somecustomers. We are currently working to enhance the framework of R&D bases in Belgium and othercountries, thereby expanding the Bio-CDMO business. On top of that, we will also focus on strengthening
our business foundation to prepare for the expansion of demand for therapeutics for genetic diseases andcancer.

④ Nutrition Solutions Unit➢

This unit recorded substantial increases in both sales and profits owing to the continued strong
performance of Supplemental Nutrition and Foods.
For Supplemental Nutrition, the sales of the active form of coenzyme Q10 remained firm in the U.S. andEurope. Sales have also grown in Asia and Oceania. We will further drive the development of new productsof the active form of coenzyme Q10 and implement various marketing measures in an effective way in andoutside Japan to expand markets.
With favorable sales in the Americas, we will push forward with the expansion of the probiotics businesson a global scale.

➢

For Foods & Agris, we made further progress in the sales shift to high-value-added products as well as in
the improvement of profit margin, greatly contributing to an improvement in profitability. For “Business toConsumer” businesses, which are a key to further business expansion, we are currently focusing on the
introduction and sales expansion of unique and distinctive high-value-added products with combining foods
and health, such as expanding the product line-up of “Watashi no Chikara (My Energy)™ - Q10 Yogurt”
and releasing new products of “Kaneka Q10™ Fruit Gummies.”(2) Financial Position for the first three months ended June 30, 2024
At the end of 1Q of the current fiscal year, total assets were ¥886,224 million, up ¥16,018 million from theprevious fiscal year-end. This is mainly due to an increase in inventories and an increase in overseas groupcompanies’ assets denominated in yen resulting from the weakening of the yen.
Liabilities totaled ¥404,832 million, up ¥9,010 million, primarily reflecting an increase in loans payable.
Net assets were ¥481,391 million, up ¥7,008 million, owing chiefly to an increase in foreign currencytranslation adjustments resulting from the weakening of the yen, and an increase in valuation difference on-4-Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

available-for-sale securities due to an increase in the fair value of shares held. Equity ratio was 51.9%.
(3) Earnings Forecasts and Other Forward-looking Statements
The global GDP growth forecast announced by the IMF in July remains at a standstill at 3.2% for 2024 and3.3% for 2025. Also, the world economy is facing the unpredictable and uncertain situation such as global
market selloff and the sharp appreciation of the yen.
Our priority business areas, Health Care SU and Nutrition SU, have continued to show steady growth. We
are planning to introduce new products in Medical and increase sales from new projects in Pharma toward
the second half, thereby accelerating the pace of growth. In Quality of Life (QoL) SU, while Performance
Fibers is facing a delayed recovery in demand, it maintains stable performance. E & I Technology isexperiencing a new demand expansion, and together with Foam & Residential Techs, whose profit margin
is currently improving, we expect earnings to expand in this unit. In Material SU, sales in Modifiers andModified Silicone polymers have been steadily growing, and we will focus on increasing sales of new
products and improving profit margin.
Under the above circumstances, we will further accelerate our company-wide portfolio transformation to
improve our profitability.
Considering the above, we have not revised the forecast for consolidated financial results announced on
May 14, 2024.

-5-

Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

2. Quarterly Consolidated Financial Statements and Main Notes(1) Quarterly Consolidated Balance Sheets(Millions of yen)

FY2023

FY2024 1st Quarter

As ofMarch 31, 2024

As ofJune 30, 2024

AssetsCurrent assets
Cash and deposits

43,96943,294

Notes and accounts receivable-trade, and contract assets

186,371

179,732

Merchandise and finished goods

94,73499,298Work in process

11,678

12,102

Raw materials and supplies

70,88376,133

Other

23,122

27,056

Allowance for doubtful accounts(1,898)(1,898)428,861435,719

Buildings and structures, net

98,883102,974

Machinery, equipment and vehicles, net

107,975

114,406

Other, net

124,460

120,726

Total property, plant and equipment

331,319

338,107

Goodwill

1,859

1,757

Other

18,973

19,328

Total intangible assets

20,832

21,086

Investment securities

70,15072,009Other

19,331

19,587

(290)

(286)

89,191

91,310441,344

450,505

870,205

886,224

Total current assets
Noncurrent assets
Property, plant and equipment

Intangible assets

Investments and other assets

Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets-6-Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)(Millions of yen)

FY2023

FY2024 1st Quarter

As ofMarch 31, 2024

As ofJune 30, 2024

Liabilities
Current liabilities
Notes and accounts payable-trade104,212

101,722

Short-term loans payable

116,532

129,376

Current portion of bonds payable

5,000

5,000

Income taxes payable

4,963

3,766

123

3

Other

60,83360,912

Total current liabilities

291,666

300,780

Bonds payable

15,00015,000Long-term loans payable

40,39140,097

Provision

2,154

1,972

Net defined benefit liability

12,585

12,250Other

34,02334,732

Total noncurrent liabilities

104,156

104,052

395,822404,832

Capital stock

33,04633,046

Capital surplus

29,17329,294Retained earnings

331,933

335,439(6,797)(11,814)387,355

385,966

32,63233,860(0)(0)

Foreign currency translation adjustment

22,03728,761Remeasurements of defined benefit plans

11,43811,308

Total accumulated other comprehensive income

66,10773,929648

648

Non-controlling interests

20,271

20,847

Total net assets

474,383

481,391

870,205

886,224

Provision

Noncurrent liabilities

Total liabilities
Net assets
Shareholders' equity

Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges

Subscription rights to shares

Total liabilities and net assets-7-

Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income(Millions of yen)

FY2023 1st Quarter FY2024 1st Quarter
From April 1, 2023
to June 30, 2023

From April 1, 2024
to June 30, 2024

Net sales

182,740

198,382

Cost of sales

136,353

142,946

Gross profit

46,38655,436

Selling, general and administrative expenses

40,78245,159Operating income

5,603

10,276

824

819

1,444

1,401

Equity in earnings of affiliates

21

37

Other

220

616

2,510

2,874

Interest expenses

750

1,016

Loss on retirement of noncurrent assets

283

540

Other

406

1,447

1,440

3,005

Ordinary income

6,674

10,146

Income before income taxes

6,674

10,146

Income taxes-current

2,431

2,931

Income taxes-deferred

(268)

(197)

Total income taxes

2,163

2,733

Net income

4,510

7,413

269

379

4,241

7,033

Non-operating income
Dividends income
Foreign exchange gains

Total non-operating income
Non-operating expenses

Total non-operating expenses

Net income attributable to non-controlling interests
Net income attributable to owners of parent-8-

Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

Quarterly Consolidated Statements of Comprehensive Income(Millions of yen)

FY2023 1st Quarter FY2024 1st Quarter
From April 1, 2023
to June 30, 2023

Net income

From April 1, 2024
to June 30, 2024

4,510

7,413

5,796

1,228

7

(0)

6,881

7,166

Remeasurements of defined benefit plans, net of tax

(71)

(130)

Share of other comprehensive income of associates accounted for using equity method(0)1

12,612

8,265

17,123

15,67816,443

14,855679

823

Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustment

Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners of parent
Comprehensive income attributable to non-controlling interests-9-Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)(3) Notes to the Consolidated Financial Statements(Changes in Accounting Policy)
The "Accounting Standard for Current Income Taxes" (ASBJ Statement No. 27, October 28, 2022; hereinafter,"Revised Accounting Standard 2022"), etc. has been applied since the beginning of the first quarter of the fiscal
year ending March 31, 2025.
The amendments to categories in which current income taxes should be recorded (taxes on othercomprehensive income) are subjected to the transitional treatment prescribed in the provison of paragraph 203 of the Revised Accounting Standard 2022 and the transitional treatment prescribed in the proviso of paragraph65-2 (2) of the Revised Implementation Guidance 2022. There are no effects on the consolidated financial
statements due to the application of the accounting standards and guidance.
Regarding the amendments related to the revision of the treatment of profits and losses on sales of shares ofsubsidiaries between consolidated companies in the case of tax deferral, the Revised Implementation Guidance
2022 has been applied from the beginning of the period for the three months ended June 30, 2024. The changein accounting policies was applied retrospectively to the consolidated financial statements for the first quarter ofthe previous fiscal year and the entire previous fiscal year. The change in the accounting policies had no impact
on the consolidated financial statements for the first quarter of the previous fiscal year or the entire previous
fiscal year.
(Segment Information)
ⅠTerm from April 1, 2023 to June 30, 2023
1) Sales and Income by Segment(Millions of yen)
Reportable Segment
Material
Solutions
Unit

Quality of Life Health Care
Solutions
Solutions
Unit
Unit

Nutrition
Solutions
Unit

Total

Others(Note 1)

Total

Adjustment

Amounts on
consolidated
financial statements(Note 2)

Sales
Customers

77,65940,87817,74546,037

182,320419

182,740－

182,740

56

9

－

10

75

280

356

(356)

－

Total

77,71640,887

17,74546,047

182,396699

183,096(356)

182,740

Segment profit

5,513

2,939

2,967

2,277

13,697288

13,985(8,381)

5,603

Intersegment

Notes: 1. “Others” is a business segment that is not included in the reportable segments and includes property
insurance and life insurance business.
2. Segment profit is reconciled with operating income in the quarterly consolidated financial statements.
2) Reconciliation between Segment Totals and Amounts on Quarterly Consolidated Financial Statements(Adjustments)(Millions of yen)
IncomeAmountSegment total

13,697

Segment profit of Others288

Elimination of intersegment transactions

1

Corporate expenses (Note)(8,393)

Other adjustments

10

Operating income in the quarterly consolidated
statements of income

5,603

Note: Corporate expenses primarily are expenses for basic R&D that are not allocable to any reportablesegments.
- 10 -

Quarterly Financial Results for the 1st Quarter, Ended June 30, 2024, Kaneka Corporation (4118)

ⅡTerm from April 1, 2024 to June 30, 2024
1) Sales and Income by Segment(Millions of yen)
Reportable Segment
Material
Solutions
Unit

Quality of Life Health Care
Solutions
Solutions
Unit
Unit

Nutrition
Solutions
Unit

Total

Others(Note 1)

Total

Adjustment

Amounts on
consolidated
financial statements(Note 2)

Sales
Customers

86,04245,05818,372

48,674

198,148234

198,382－

198,382

58

20

12

11

103

309

413

(413)

－

Total

86,10145,07918,384

48,686198,251544

198,796(413)

198,382

Segment profit

8,382

4,256

2,992

3,903

19,535111

19,646(9,369)10,276

Intersegment

Notes: 1. “Others” is a business segment that is not included in the reportable segments and includes property
insurance and life insurance business.
2. Segment profit is reconciled with operating income in the quarterly consolidated financial statements.
2) Reconciliation between Segment Totals and Amounts on Quarterly Consolidated Financial Statements(Adjustments)(Millions of yen)
IncomeAmountSegment total

19,535

Segment profit of Others

111

Elimination of intersegment transactions

0

Corporate expenses (Note)(9,399)Other adjustments

29

Operating income in the quarterly consolidated
statements of income

10,276

Note: Corporate expenses primarily are expenses for basic R&D that are not allocable to any reportablesegments.
(Notes in the Event of Significant Changes in the Amount of Shareholders’ Equity)
Not applicable(Going Concern Assumption)
Not applicable(Notes on Quarterly Consolidated Statements of Cash Flows)
The quarterly consolidated statement of cash flows for the three months ended June 30, 2024 has not been
prepared. Depreciation (including amortization of intangible assets other than goodwill) and amortization of
goodwill for the three months ended June 30, 2023 and June 30, 2024 is as follows:(Millions of yen)
FY2024 1st Quarter

FY2023 1st Quarter
From April 1, 2023
to June 30, 2023

Depreciation
Amortization of Goodwill- 11 -

From April 1, 2024
to June 30, 2024
9,947

10,559161

184